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Abstract: Endothelial cells are the main determinants of vascular function, since their dysfunction in
response to a series of cardiovascular risk factors is responsible for disease progression and further
consequences. Endothelial dysfunction, if not resolved, further aggravates the oxidative status
and vessel wall inflammation, thus igniting a vicious cycle. We have furthermore to consider the
physiological manifestation of vascular dysfunction and chronic low-grade inflammation during
ageing, also known as inflammageing. Based on these considerations, knowledge of the molecular
mechanism(s) responsible for endothelial loss-of-function can be pivotal to identify novel targets of
intervention with the aim of maintaining endothelial wellness and vessel trophism and function.
In this review we have examined the role of the detoxifying enzyme aldehyde dehydrogenase
2 (ALDH2) in the maintenance of endothelial function. Its impairment indeed is associated with
oxidative stress and ageing, and in the development of atherosclerosis and neurodegenerative diseases.
Strategies to improve its expression and activity may be beneficial in these largely diffused disorders.
Keywords: endothelial cells; oxidative stress; inflammageing; endothelial dysfunction; aldehyde
dehydrogenase-2; cardiovascular disease; neurovascular disease
1. Introduction
We searched PubMed from its inception up to December, 2019, using the terms “ALDH2,
endothelial cells, endothelial dysfunction, endothelial senescence, ageing, oxidative stress,
inflammageing, cardiovascular diseases, neurovascular diseases” to identify publications in English
that described the mechanism of action of ALDH2 activity in vascular function, preclinical evidence
of beneficial effects of ALDH2 expression/activity for endothelial function, or clinical evidence of
the benefit of ALDH2 activity modulation in cardio- or neuro-vascular diseases. We mostly selected
publications from the past 10 years that we judged were relevant, but we did not exclude widely
referenced and highly regarded older publications.
1.1. Endothelial Function and Dysfunction
Vascular function such as the heartbeat is an essential system for the good functioning of our body.
Under normal conditions, endothelial cells (ECs) in blood vessels, through the release of vasoactive
and anti-aggregatory mediators and the functioning of antioxidant systems, regulate blood pressure,
protecting from hypertension and atherosclerosis. They also constitute a blood barrier, preventing
leukocyte infiltration and inflammation into the vascular wall and surrounding tissues [1,2].
Conversely, endothelial dysfunction has been identified as a hallmark of most cardiovascular
diseases. Dysfunction of ECs is correlated with an imbalance in the production of key regulators
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of the vascular homeostasis such as nitric oxide (NO) and growth factors, and/or impaired activity
(uncoupling) of endothelial NO synthase (eNOS), associated with increased reactive oxygen species
(ROS) levels and vascular oxidative stress [3,4]. Inflammatory factors such as inteleukin-6 (IL-6), tumor
necrosis factor-α (TNF-α), intercellular adhesion molecule 1 (ICAM-1) and loss of the antioxidant
mechanism are among the most important causes of vascular dysfunction [5].
When endothelial dysfunction occurs, the ability of endothelium to perform one or all of these
functions is decreased. In this condition, ECs switch to a pro-inflammatory profile, characterized by
loss of barrier integrity, and reduced release of vasoactive molecules associated with increased release
of pro-thrombotic mediators [2,5]. Our studies and those of others showed that endothelial dysfunction
is linked to impaired endothelial cell survival and physiological angiogenic outcomes with a later
rearrangement of the microcirculation that contributes to the onset of various diseases [6–8]. Both anti-
and pro-angiogenic therapeutic strategies have been developed for treating human diseases. While
angiogenesis inhibitors have been shown to have success in many diseases as cancer, few treatment
protocols with the aim to stimulate angiogenesis in ischemia-associated diseases have reached the
clinic. Indeed, since endothelial function has been proposed as “barometer for cardiovascular risk”,
identification of the molecular determinants underlying endothelial integrity and functionality is
a medical need [5,6,9–11]. In this scenario, risk factors for endothelial dysfunction are represented
by pathological conditions as hypertension, diabetes and atherosclerosis, and lifestyles as high-fat
diet, tobacco smoke, alcohol intake, and physical inactivity [12]. Since endothelium is a regulator of
exchanges between the vascular wall and surrounding tissues, it is not surprising that dysfunctional
ECs can lead to the impairment of other tissues [2,6,12]. Indeed, assessment of vascular function
and structure, and in particular of endothelial dysfunction appears to play a crucial role in a broad
array of human diseases as cardiovascular and neurodegenerative diseases, tumor growth and
metastasis [2,5,8–12].
1.2. Endothelial Senescence
Cardiovascular diseases (CVDs) represent the major cause of disability and death in the elderly
population of the Western World. As introduced above, a large number of risk factors plays a
role in the development of CVDs, especially ageing which is associated with well-characterized
phenotypes [8,13,14]. Over time, aged blood vessels become stiffer and thicker, and their ability to release
vasoactive mediators, particularly NO, decreases, while vascular permeability increases, associated
with the process of mild vessel inflammation, increased vessel thickness and compromised angiogenic
response [14–18]. Of note, even if age remains the main determinant of vascular senescence, healthy
vascular ageing can be achieved, and endothelial function is a key element of the heathy vasculature.
Senescent vascular endothelium and other tissues are frequently characterized by chronic mild
inflammation [12,13]. In particular, the age-related low grade, chronic, and systemic inflammation
is indicated by the term “inflammageing” [12,13]. The indicators of inflammageing include elevated
levels of inflammatory mediators such as IL-1, IL-6 and TNF-α, which characterize many age-related
pathological phenotypes. These indicators derive from an imbalance of the immune response
(immunosenescence) [19].
A large population of senescent cells in organs has the potential to negatively impact organ
renewal capabilities and functions, especially on ECs, accelerating the onset of several age-associated
pathologies, as CVDs and cancer [15,20].
However, senescent cells may also exert various positive effects on individuals. As senescence
is associated with irreversible growth arrest, it is considered to be a tumor suppressor process [21].
In particular, indirect evidence indicates that endothelial senescence plays a causal role in microvascular
rarefaction and affects the ability of cells to proliferate and form capillary-like structures [20]. The timely
and challenging issue for modern biomedical sciences focused on ageing is the identification of the
biological targets and the pharmacological tools able to promote “healthy ageing”.
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1.3. Aldehyde Dehydrogenase-2 (ALDH2)
The aldehyde dehydrogenase (ALDH) gene superfamily encodes enzymes that are mainly
responsible for the irreversible oxidation of various aldehydes. Three major classes of mammalian
ALDHs (classes 1, 2 and 3) have been identified. Classes 1 and 3 contain both constitutive and
inducible cytosolic isozymes. Class 2 consists of constitutive mitochondrial isozymes [22,23].
ALDH2 is primarily involved in the detoxification of acetaldehyde, the first intermediate of ethanol
metabolism, into acetate, a less active byproduct [23]. In addition to acetaldehyde, other aldehydes are
metabolized by ALDH2 [23,24]. The sources of aldehydic substrates of ALDH2 can be endogenous or
exogenous. Endogenous reactive aldehydes are generated as byproducts of cell metabolism and include
malondialdehyde, 4-hydroxynonenal (4-HNE), DOPAL, and acrolein [23]. Exogenous aldehydes are
found in industrial and environmental pollutants and may be produced during metabolism of
xenobiotics. Among these, acrolein, acetaldehyde and formaldehyde are the major reactive species
found in tobacco smoke and car exhaust [23,24]. Generally, aldehydes are toxic molecules that react
rapidly with amino acid residues, e.g., thiols to form the genotoxic DNA- and protein-adducts in
cells [23,24].
ALDH proteins are found in all cellular compartments, including cytosol, mitochondria,
endoplasmic reticulum and the nucleus. Some proteins have more than one cellular location.
Nevertheless, ALDHs also catalyze some reactions involved in the formation of bioactive molecules
that regulate important physiological functions. This is the case of some ALDHs as ALDH1A1, 1A2
and 1A3 that convert retinal aldehyde in retinoic acid. In turn, retinoic acid acts as a ligand for
retinoic X receptor (RXR) and nuclear retinoic receptor (RAR), participating in a number of growth and
developmental processes [23,25,26].
ALDH2 arises as an important gatekeeper of ROS overproduction that a cell is able to tolerate.
In fact, the main function of mitochondrial ALDH2 is to protect mitochondria and cells from
the damaging effect of aldehydes, by oxidizing the substrates into their corresponding non-toxic
carboxylic acids. Some studies distinguish between direct and indirect anti-oxidative properties
of ALDH2. The direct anti-oxidative properties are assumed to depend on its potent reductase
function with its highly activated sulfhydryl groups [27]. In addition to oxidative capabilities, ALDH2
possesses nitrate reductase activity responsible for the bioconversion of nitroglycerin to 1,2-glyceryl
dinitrate (GDN), thus inducing NO release [28–30]. ALDH2 protein can be the substrate of various
post-translational modifications, including oxidation, S-nitrosylation, phosphorylation, nitration,
acetylation, glycosylation, and adduct formation, most of which reduce its activity [31].
In the present review, we describe the effects of oxidative stress-linked accumulation of aldehydes
in the cells, focusing on ECs, and discuss the contribution of ALDH2 in several endothelium-dependent
disorders, including senescence.
2. ALDH2 and Endothelial-Related Diseases
Different diseases have in common EC impairment and dysfunction and more precisely an
alteration in ALDH expression and enzymatic activity, in turn responsible for changes in oxidative
status and inflammation (Figure 1).
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Figure 1. The role of aldehyde dehydrogenase-2 (ALDH2) in endothelial function and 
endothelial-related diseases. ALDH2 downregulation (down arrow) and/or catalytic inactivation 
(dashed red lines) into mitochondria in endothelial cells (ECs), leading to inefficient aldehyde 
metabolism, is recognized to affect endothelial functions and make senescence occur faster. 
Senescence itself might further aggravate endothelial dysfunction. In turn, ALDH2 is believed to be 
involved in the ageing process, in particular ageing related-cardiovascular diseases, such as 
atherosclerosis and coronary artery disease (CAD), and affect the cerebrovascular unit, contributing 
to the etiology of neurovascular degenerative diseases, including Cerebral Amyloid Angiopathy 
(CAA). 
2.1. ALDH2, Oxidative Stress and Ageing 
Advanced age is an independent risk factor for life-threatening diseases, including coronary 
artery disease, stroke, and neurodegenerative diseases, which are directly related to 
ageing-associated EC dysfunction [32]. Despite senescence being studied deeply for many centuries 
and many steps in our understanding of it accomplished, the process of ageing remains largely 
difficult to remedy and remains, unfortunately, inevitable [33]. In addition to the “inflammageing” 
hypothesis, many theories have been proposed to explain the process of ageing [33]. In particular, 
the general free radical theory of ageing indicates that ageing is caused by ROS-dependent 
accumulation of damage [34]. In other words, the traditional view in the field of free radical biology 
is that free radicals and ROS are toxic and able to directly damage a large plethora of biological 
targets. Furthermore, the accumulation of damage leads to the process of ageing resulting in various 
diseases [35]. Recent findings revealed that the accumulation of toxic aldehydes plays a key role in 
ischemia-reperfusion injuries and in ageing as much as ROS from which they derive [36–39]. 
Accordingly, some studies support the close link between ALDH2 dysfunction and ageing, 
especially in the heart [40,41]. In particular, ALDH2 has been reported to protect ECs against 
oxidative stress events due to aldehydes, and cell senescence [41,42]. 
One of our recent works showed that inhibition of ALDH2 activity negatively impacted EC 
function. We demonstrated that ALDH2 silencing or inhibition significantly affected cell 
proliferation, migration and altered cellular permeability, in terms of reduced VE–cadherin and 
ZO-1 expression at cell–cell contacts and increased cellular permeability in human umbilical vein 
endothelial cells (HUVECs) [42]. Although the mechanism of action has not been fully elucidated, 
our results indicate that ROS production and 4-hydroxy-2-nonenal (4-HNE) accumulation, a 
Figure 1. The role of aldehyde dehydrogenase-2 (ALDH2) in endothelial function and
endothelial-related diseases. ALDH2 downregulation (down arrow) and/or catalytic inactivation
(dashed red lines) into mitochondria in endothelial cells (ECs), leading to inefficient aldehyde
metabolism, is recognized to affect endothelial functions and make senescence occur faster. Senescence
itself might further aggravate endothelial dysfunction. In turn, ALDH2 is believed to be involved in
the ageing process, in particular ageing related-cardiovascular diseases, such as atherosclerosis and
coronary artery disease (CAD), and affect the cerebrovascular unit, contributing to the etiology of
neurovascular degenerative diseases, including Cerebral Amyloid Angiopathy (CAA).
2.1. ALDH2, Oxidative Stress and Ageing
Advanced age is an independent risk factor for life-threatening diseases, including coronary
artery disease, stroke, and neurodegenerative diseases, which are directly related to ageing-associated
EC dysfunction [32]. Despite senescence being studied deeply for many centuries and many steps in
our understanding of it accomplished, the process of ageing remains largely difficult to remedy and
remains, unfortunately, inevitable [33]. In addition to the “inflammageing” hypothesis, any theories
have been proposed to explain the process of ageing [33]. In particular, the general free radical theory
of ageing indicates that ageing is caused by ROS-dependent accumulation of damage [34]. In other
words, the traditional view in the field of free radical biology is that free radicals and ROS are toxic
and able to directly damage a large plethora of biological targets. Furthermore, the accumulation of
damage leads to the process of ageing resulting in various diseases [35]. Recent findings revealed that
the accumulation of toxic aldehydes plays a key role in ischemia-reperfusion injuries and in ageing as
much as ROS fro which they derive [36–39].
Accordingly, some studies support the close link between ALDH2 dysfunction and ageing,
especially in the heart [40,41]. In particular, ALDH2 has been reported to protect ECs against oxidative
stress events due to aldehydes, and cell senescence [41,42].
One of our recent works showed that inhibition of ALDH2 activity negatively impacted EC
function. We demonstrated that ALDH2 silencing or inhibition significantly affected cell proliferation,
migration and altered cellular permeability, in terms of reduced VE–cadherin and ZO-1 expression
at cell–cell contacts and increased cellular permeability in human umbilical vein endothelial cells
(HUVECs) [42]. Although the mechanism of action has not been fully elucidated, our results indicate
that ROS production and 4-hydroxy-2-nonenal (4-HNE) accumulation, a secondary end-product of
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lipid peroxidation, contribute to mediate endothelial dysfunction and the onset of senescence in
siALDH2 and daidzin-treated cells [42]. These findings were supported by the observation that
exposure to the ROS scavenger, N-acetylcysteine, affected the pattern of 4-HNE adducts, reduced ROS
and recovered cell survival in siALDH2 cells [42]. The aldehyde 4-HNE is a reactive molecule which
forms adducts with proteins, lipids and DNA. Excessive 4-HNE adduct formation has been reported
in ischemic cardiovascular tissue isolated from rodents and humans [43,44]. From a bioenergetic
standpoint, we observed that ALDH2 attenuation reduced basal and maximal respiration and abolished
mitochondrial reserve capacity in ECs [42]. Intriguingly, this latter finding suggested that ALDH2
supports mitochondrial bioenergetics by increasing basal, maximal and consequently reserve capacity.
Further, the changes in cell morphology, from polygonal to an enlarged and irregular shape, evoked
the senescent phenotype and this led us to explore further details. The analysis of typical senescent
markers, such as p21/p53 expression and SA-β-gal, further suggested that siALDH2 or daidzin-treated
ECs present early signs of senescence [42]. This scenario suggests a protective role of ALDH2 on
endothelium. The inhibition of ALDH2 affects endothelial functions, bioenergetics and metabolism,
and makes the acquisition of a senescent phenotype faster. The acquisition of a senescent phenotype
might have a defensive role, but the expansion of senescent cells might itself further aggravate the
damage and accelerate ageing.
From a mechanistic point of view, the accumulation of endogenous reactive aldehydes,
including 4-HNE, and inhibition of ALDH2 by these reactive species increased cell vulnerability
to aldehyde-induced damage [45]. Indeed, susceptibility to lipid peroxidation byproducts of ALDH2
enzymatic activity was reported [46]. It was observed that ALDH2 is inactivated by aldehydes at
low concentrations (<10 µM) and ROS. ALDH inactivation may interfere with the detoxification of
lipid aldehydes, promoting their accumulation, which, in turn, is known to trigger ROS production,
amplifying oxidative damage in the cell. Specifically, in ECs inactivation of ALDH2 correlates with
vascular damage, vasoconstriction, and thrombosis [47].
Moreover, evidence showed the role of acetaldehyde in tissue and cell damage. In particular, a study
reported that ALDH2 prevented acetaldehyde-related toxic effects by alleviating oxidative stress and
apoptosis in HUVECs [47]. For instance, it has been observed that in HUVEC, ALDH2 over-expression
protects cells from the toxic effects of exposure to different concentrations of acetaldehyde. As a
result, the generation of ROS is decreased, as well as apoptosis and activation of stress signaling
molecules, such as signal-regulated extracellular kinases (ERK1/2), and the p38 mitogenic activated
MAP kinase protein [47]. Of note, the acetaldehyde-induced ROS generation, apoptosis and activation
of stress molecules were prevented by the ALDH2 transgene in a manner similar to antioxidant
alpha-tocopherol, indicating that facilitation of acetaldehyde detoxification by ALDH2 transgene
overexpression is able to counteract acetaldehyde-induced EC injury and activation of stress signals.
These data consecutively highlight the therapeutic potential of ALDH2 in the prevention of cell damage
induced by ethanol consumption [47], features of which are very similar to those of accelerated ageing.
Consistently, mutations in ALDHs genes as well as their downregulation or ALDHs catalytic
inactivation, leading to inefficient aldehyde metabolism, may contribute in the etiology of various
diseases including cardiopathies and neurovascular degenerative diseases, including the cerebral
amyloid angiopathy (CAA) and Alzheimer’s disease (AD) [24,48].
2.2. ALDH2 and Atherosclerosis
Heart failure is a clinical manifestation characterized by alterations in cardiac morphology and
functions that lead to reduced cardiac output and/or elevated intra-cardiac pressure at rest or during
stress. Coronary artery disease (CAD), diabetes mellitus and alcohol abuse are common determinants
of myocardial diseases, which result in ischemic injury, metabolic disorders or toxic damage [49].
Nevertheless, advanced ageing leads to alteration in morphology and function of the heart in the
absence of other accompanying cardiovascular risk factors. In particular, ALDH2 is believed to be
involved in the ageing process and ageing related-cardiovascular diseases. In fact, although ALDH2
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is better known for its involvement in ethanol metabolism, it is also crucial for cardioprotection
through the detoxification of reactive aldehydes such as 4-HNE and the bioconversion of nitrates into
NO [27,29]. ALDH2 is largely seen as a critical enzyme involved in protecting the heart from ischemic
injury. Much evidence, including meta-analysis, have assessed the associations between ALDH2
rs671 (ALDH2*2) polymorphism inactivating the enzymatic activity, and CAD [50]. Additionally,
results from various studies conducted on Asian patients have highlighted the strong association
between myocardial infarction and ALDH2 rs671 polymorphism [51]. In this context, the majority of
studies focused on myocardium [52], with limited attention on ECs or vessels. Nonetheless, ALDH2
activity is impaired by oxidized low-density lipoproteins (ox-LDLs), possibly by post-translational
modifications. In particular, ox-LDLs are found to exert an inhibitory effect on ALDH2 activity by
preventing mitochondrial sirtuin 3 (SIRT3) expression [31]. SIRT3 is one of the members of the sirtuin
family, which have a common core domain and an important role in ageing, stress resistance and
metabolic regulation. In particular, SIRT3 has received much attention for its role in mitochondrial
metabolism and ageing [53].
A study corroborates the association between ALDH2 and SIRT3 [54]. This study strengthens the
concept that moderate ethanol consumption is associated with a positive effect on eNOS activation
that results in antiatherogenic actions. In particular, Xue and colleagues showed that in human aortic
ECs (HAECs), low-dose ethanol resulted in SIRT3 inactivation, leading to rapid activation of ALDH2.
ALDH2 activity mediates ethanol-induced eNOS activation and prevents ROS accumulation [54].
Thus, ALDH2 activation promoted by SIRT3 inactivation improves HAEC function, resulting in
an anti-atherogenic effect. Consistent with this finding, another recent study showed that ALDH2
silencing or inhibition aggravated the atherosclerotic process. In ApoE−/− mice the silencing of the
ALDH2 gene was associated with a severe inflammation of the vascular wall and the formation of larger
and more unstable plaques [55]. In-vitro experiments with HUVECs further illustrated that inhibition
of ALDH2 activity resulted in elevated inflammatory molecules, an enhanced nuclear translocation or
phosphorylation of pro-inflammatory transcription factor such as NF-κB or AP-1 involved in vessel
permeability and plaque development [55]. Of note, in ECs, we and other reported that several natural
agents such as polyphenols of extra virgin olive oil modulate, beyond ROS production, the expression
and activity of enzymes and transcription factors involved in atherogenesis [56,57]. These data support
the assumption that metabolic cell redox state has a marked impact on the cell transcriptome and
proteome, and, in turn, on cell functions. In this context, it would be of interest to know the effects of
nutraceuticals on ALDH2 activity in controlling vessel integrity.
Overall, these data convincingly indicate that ALDH2 silencing or inhibition exacerbates
the atherosclerosis process, increasing plaque development and vulnerability with aggravated
inflammation. Nevertheless, further work is needed to fully understand the clinical value of ALDH2
and its activation in the prevention or treatment of atherosclerotic diseases, such as CAD.
2.3. ALDH2 and Neurodegenerative Diseases
Alzheimer’s disease (AD) is classified as a progressive neurodegenerative disorder, characterized
by neuropathological changes in particular brain regions and in a variety of neuro-transmitter systems.
The progressive neuronal degeneration that occurs in AD generally leads to dementia, the most common
consequence, affecting cognitive functions in patients such as memory, thinking and reasoning [58].
Unfortunately, AD is becoming more prevalent as human lifespan increases. AD is a multifactorial
disease driven by a combination of genetic and environmental factors and can be divided in two
forms: familial and sporadic cases [59]. A characteristic feature of AD is the deposit of amyloid β
peptides (mainly Aβ1-40 and Aβ1-42) in the brain that form extracellular amyloid plaques. These
plaques lead to neuronal dysfunction, cell death, and loss of synaptic connections, notably due to
the ensuing inflammation and oxidative stress [60]. Increased oxidative stress is reported to play a
critical role in the pathogenesis of AD prior to the onset of Aβ deposition and cognitive impairment.
Cerebrovascular dysfunction has emerged as a critical feature of neurodegenerative diseases [61].
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Cerebral amyloid angiopathy (CAA), a cerebrovascular disease that is frequently associated with
AD, is characterized by the accumulation of Aβ in cerebral microvessels. In CAA, the endothelial
dysfunction is thought to alter Aβ homeostasis and to promote infiltration of the brain parenchyma
with circulating toxic molecules [61]. At the same time, Aβ peptides, especially the vasculotropic
isoform Aβ1–40, affect brain blood vessels, altering their fundamental functions, including impairment
of vasoactive tone and barrier functions, vascular remodelling as well as suppression of the intrinsic
angiogenic properties of endothelium [48,62–64]. Although CAA remains clinically distinct from AD,
their common features have the potential to link cerebrovascular and neurodegenerative pathways in
the ageing brain. The product 4-HNE is formed during oxidative stress, and is able to react with many
molecules such as proteins, and to accumulate in the brain. Many studies have shown that 4-HNE
covalently modifies Aβ via 1,4 conjugates, altering the function of Aβ and impairing cellular features
such as metabolism, cell signaling and structural integrity [65]. Since ALDH2 protects mitochondrial
functions through the detoxification of 4-HNE that accumulates in this organelle, it is not surprising
that recent epidemiological studies showed a correlation between ALDH2*2 loss-of-function mutations
in Asian patients and a higher incidence of AD in these people [24,45].
One potential intervention for the treatment of AD can be to reduce the toxicity caused by the
Aβ peptides, particularly Aβ1-40. Previous studies from our lab elucidated the role of ALDH2 in the
protection of endothelium against Aβ1-40 damage. In particular, the chronic exposure of cultured EC
to Aβ results in profound modifications of cell pro-angiogenic functions, shifting their phenotype
toward the senescence program and reducing its pro-angiogenic capability [66]. Aβ peptides also
increase intracellular 4-HNE in ECs by impairment of mitochondrial ALDH2 activity [48]. Consistently,
in an ALDH2−/− knockout null mouse model, mice exhibited both neuronal and vascular pathological
changes associated with AD. In fact, mice exhibited progressive, age-related cognitive deficits in
non-spatial and spatial working memory and other features, together with a multitude of AD-associated
signs, including 4-HNE adducts as well as age-related increase in Aβ [67].
In addition to the observed AD-like changes in the brain, significant vascular alterations were
found in cerebral microvessels (CMVs) of ALDH2−/− mice. In comparison to the wild type, CMVs
of these mice displayed marked increases in HNE adducts and age-related increases in monomeric
Aβ. Moreover, ALDH2−/− mice exhibited endothelial dysfunction, and increased Aβ deposits in
microvessels [67].
From these studies it seems that ALDH2 activity may play a critical role for preserving endothelial
function in cerebrovascular units and preventing age-related dysfunctions.
3. Conclusions
Global average lifespan is increasing as a result of many factors, such as lifestyle. But, as longevity
continues to increase, ageing-related diseases and, consequentially, the need for new therapeutic
interventions arise. Today, regenerative medicine plays a significant role relative to other therapies,
including those for the treatment of CVD.
In this review we showed that ALDH2 asserts a protective role in the endothelium against different
types of stressors including age-associated dysfunctions. ALDH2 has emerged in recent years as a
crucial guardian against several stressor or toxic insults, supporting its potential role in many diseases,
including cardiovascular and cerebrovascular diseases that are linked to ageing (Table 1).
Since senescence-related endothelial dysfunction plays a crucial role in the pathogenesis of several
diseases, further studies are necessary to fully elucidate the role and protective mechanisms of ALDH2
in the endothelium.
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Table 1. Summary of main findings of ALDH2 and ageing, atherosclerosis or neurodegenerative
diseases.
ALDH2 Status Tissue/Cells Molecular Mechanism Function Ref.
ALDH2 and vascular ageing
ALDH2 activation Heart (rat) (−) aldehydic adducts(carbonylation) (−) cardiac dysfunction [28]
ALDH2 activation Liver (rat)
(−) ROS
(−) pro-inflammatory
cytokines
(−) 4-HNE and MDA
(−) tissue apoptosis
(+) mitochondrial
membrane potential
[30]
ALDH2 transgenic
mice Heart
(+) ROS
(−) AMPK phosphorylation
(−) SIRT1
(+) ageing-induced
cardiac hypertrophy
(+) apoptosis
(+) mitochondrial injury
[40]
ALDH2 activation Heart (mouse)
(−) 4-HNE-protein adducts
(−) protein carbonyls
(+) autophagy flux
(+) SIRT1
(+) cardiac function [41]
ALDH2 gene
silencing Endothelial cells
(+) ROS
(+) 4-HNE
(−) respiration
(+) senescence [42]
ALDH2 gene
transfection Endothelial cells (−) ROS
(−) apoptosis
(−) ERK/p38-MAPK [47]
ALDH2 and atherosclerosis
ALDH2*2
loss-of-function — (+) ox-LDLs
(+) coronary artery
disease [50–52]
ALDH2 gene
silencing ApoE
−/− mice (+) ROS
(+) vessel wall
inflammation
(+) plaque instability
[55]
ALDH2 activation Endothelial cells (−) ROS; (+) eNOS(−) SIRT3 activation — [54]
ALDH2 inhibition Endothelial cells (+) NF-κB(+) AP-1
(+) permeability
(+) plaque formation [55]
ALDH2 and neurodegenerative diseases
ALDH2*2
loss-of-function Brain —
(+) incidence of
Alzheimer’s disease [45]
ALDH2−/− mouse
model
Brain (+) 4-HNE adducts(+) Aβ
(+) cognitive deficits
(+) endothelial
dysfunction
(+) Aβ in microvessels
[47]
ALDH2 inactivation Endothelial cells (+) 4-HNE (−) angiogenesis(+) senescence [48]
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